Search

Your search keyword '"Graham, Mindy K."' showing total 7 results
Start Over Author "Graham, Mindy K." Publication Type Electronic Resources
7 results on '"Graham, Mindy K."'

1. Telomere alterations in neurofibromatosis type 1-associated solid tumors.

Author

Rodriguez, Fausto J, Rodriguez, Fausto J, Graham, Mindy K, Brosnan-Cashman, Jacqueline A, Barber, John R, Davis, Christine, Vizcaino, M Adelita, Palsgrove, Doreen N, Giannini, Caterina, Pekmezci, Melike, Dahiya, Sonika, Gokden, Murat, Noë, Michael, Wood, Laura D, Pratilas, Christine A, Morris, Carol D, Belzberg, Allan, Blakeley, Jaishri, Heaphy, Christopher M, Rodriguez, Fausto J, Rodriguez, Fausto J, Graham, Mindy K, Brosnan-Cashman, Jacqueline A, Barber, John R, Davis, Christine, Vizcaino, M Adelita, Palsgrove, Doreen N, Giannini, Caterina, Pekmezci, Melike, Dahiya, Sonika, Gokden, Murat, Noë, Michael, Wood, Laura D, Pratilas, Christine A, Morris, Carol D, Belzberg, Allan, Blakeley, Jaishri, and Heaphy, Christopher M

Abstract

The presence of Alternative lengthening of telomeres (ALT) and/or ATRX loss, as well as the role of other telomere abnormalities, have not been formally studied across the spectrum of NF1-associated solid tumors. Utilizing a telomere-specific FISH assay, we classified tumors as either ALT-positive or having long (without ALT), short, or normal telomere lengths. A total of 426 tumors from 256 NF1 patients were evaluated, as well as 99 MPNST tumor samples that were sporadic or of unknown NF1 status. In the NF1-glioma dataset, ALT was present in the majority of high-grade gliomas: 14 (of 23; 60%) in contrast to only 9 (of 47; 19%) low-grade gliomas (p = 0.0009). In the subset of ALT-negative glioma cases, telomere lengths were estimated and we observed 17 (57%) cases with normal, 12 (40%) cases with abnormally long, and only 1 (3%) case with short telomeres. In the NF1-associated malignant nerve sheath tumor (NF1-MPNST) set (n = 75), ALT was present in 9 (12%). In the subset of ALT-negative NF1-MPNST cases, telomeres were short in 9 (38%), normal in 14 (58%) and long in 1 (3%). In the glioma set, overall survival was significantly decreased for patients with ALT-positive tumors (p < 0.0001). In the NF1-MPNST group, overall survival was superior for patients with tumors with short telomeres (p = 0.003). ALT occurs in a subset of NF1-associated solid tumors and is usually restricted to malignant subsets. In contrast, alterations in telomere lengths are more prevalent than ALT.

Published
2019

2. Publisher Correction : Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors (Nature Medicine, (2019), 25, 8, (1260-1265), 10.1038/s41591-019-0493-4)

Author

Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M A, Brosens, Lodewijk A A, Deshpande, Vikram, Epstein, Charles B, Conemans, Elfi B, Morsink, Folkert H M, Graham, Mindy K, Valk, Gerlof D, Vriens, Menno R, Castillo, Carlos Fernandez-Del, Ferrone, Cristina R, Adar, Tomer, Bowden, Michaela, Whitton, Holly J, Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W, Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M, Sicinska, Ewa, Kulke, Matthew H, Chung, Daniel C, Bernstein, Bradley E, Shivdasani, Ramesh A, Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M A, Brosens, Lodewijk A A, Deshpande, Vikram, Epstein, Charles B, Conemans, Elfi B, Morsink, Folkert H M, Graham, Mindy K, Valk, Gerlof D, Vriens, Menno R, Castillo, Carlos Fernandez-Del, Ferrone, Cristina R, Adar, Tomer, Bowden, Michaela, Whitton, Holly J, Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W, Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M, Sicinska, Ewa, Kulke, Matthew H, Chung, Daniel C, Bernstein, Bradley E, and Shivdasani, Ramesh A

Published
2019

3. Publisher Correction : Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors (Nature Medicine, (2019), 25, 8, (1260-1265), 10.1038/s41591-019-0493-4)

Author

Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M A, Brosens, Lodewijk A A, Deshpande, Vikram, Epstein, Charles B, Conemans, Elfi B, Morsink, Folkert H M, Graham, Mindy K, Valk, Gerlof D, Vriens, Menno R, Castillo, Carlos Fernandez-Del, Ferrone, Cristina R, Adar, Tomer, Bowden, Michaela, Whitton, Holly J, Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W, Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M, Sicinska, Ewa, Kulke, Matthew H, Chung, Daniel C, Bernstein, Bradley E, Shivdasani, Ramesh A, Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M A, Brosens, Lodewijk A A, Deshpande, Vikram, Epstein, Charles B, Conemans, Elfi B, Morsink, Folkert H M, Graham, Mindy K, Valk, Gerlof D, Vriens, Menno R, Castillo, Carlos Fernandez-Del, Ferrone, Cristina R, Adar, Tomer, Bowden, Michaela, Whitton, Holly J, Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W, Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M, Sicinska, Ewa, Kulke, Matthew H, Chung, Daniel C, Bernstein, Bradley E, and Shivdasani, Ramesh A

Published
2019

4. Telomere alterations in neurofibromatosis type 1-associated solid tumors.

Author

Rodriguez, Fausto J, Rodriguez, Fausto J, Graham, Mindy K, Brosnan-Cashman, Jacqueline A, Barber, John R, Davis, Christine, Vizcaino, M Adelita, Palsgrove, Doreen N, Giannini, Caterina, Pekmezci, Melike, Dahiya, Sonika, Gokden, Murat, Noë, Michael, Wood, Laura D, Pratilas, Christine A, Morris, Carol D, Belzberg, Allan, Blakeley, Jaishri, Heaphy, Christopher M, Rodriguez, Fausto J, Rodriguez, Fausto J, Graham, Mindy K, Brosnan-Cashman, Jacqueline A, Barber, John R, Davis, Christine, Vizcaino, M Adelita, Palsgrove, Doreen N, Giannini, Caterina, Pekmezci, Melike, Dahiya, Sonika, Gokden, Murat, Noë, Michael, Wood, Laura D, Pratilas, Christine A, Morris, Carol D, Belzberg, Allan, Blakeley, Jaishri, and Heaphy, Christopher M

Abstract

The presence of Alternative lengthening of telomeres (ALT) and/or ATRX loss, as well as the role of other telomere abnormalities, have not been formally studied across the spectrum of NF1-associated solid tumors. Utilizing a telomere-specific FISH assay, we classified tumors as either ALT-positive or having long (without ALT), short, or normal telomere lengths. A total of 426 tumors from 256 NF1 patients were evaluated, as well as 99 MPNST tumor samples that were sporadic or of unknown NF1 status. In the NF1-glioma dataset, ALT was present in the majority of high-grade gliomas: 14 (of 23; 60%) in contrast to only 9 (of 47; 19%) low-grade gliomas (p = 0.0009). In the subset of ALT-negative glioma cases, telomere lengths were estimated and we observed 17 (57%) cases with normal, 12 (40%) cases with abnormally long, and only 1 (3%) case with short telomeres. In the NF1-associated malignant nerve sheath tumor (NF1-MPNST) set (n = 75), ALT was present in 9 (12%). In the subset of ALT-negative NF1-MPNST cases, telomeres were short in 9 (38%), normal in 14 (58%) and long in 1 (3%). In the glioma set, overall survival was significantly decreased for patients with ALT-positive tumors (p < 0.0001). In the NF1-MPNST group, overall survival was superior for patients with tumors with short telomeres (p = 0.003). ALT occurs in a subset of NF1-associated solid tumors and is usually restricted to malignant subsets. In contrast, alterations in telomere lengths are more prevalent than ALT.

Published
2019

5. Publisher Correction : Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors (Nature Medicine, (2019), 25, 8, (1260-1265), 10.1038/s41591-019-0493-4)

Author

Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M A, Brosens, Lodewijk A A, Deshpande, Vikram, Epstein, Charles B, Conemans, Elfi B, Morsink, Folkert H M, Graham, Mindy K, Valk, Gerlof D, Vriens, Menno R, Castillo, Carlos Fernandez-Del, Ferrone, Cristina R, Adar, Tomer, Bowden, Michaela, Whitton, Holly J, Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W, Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M, Sicinska, Ewa, Kulke, Matthew H, Chung, Daniel C, Bernstein, Bradley E, Shivdasani, Ramesh A, Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M A, Brosens, Lodewijk A A, Deshpande, Vikram, Epstein, Charles B, Conemans, Elfi B, Morsink, Folkert H M, Graham, Mindy K, Valk, Gerlof D, Vriens, Menno R, Castillo, Carlos Fernandez-Del, Ferrone, Cristina R, Adar, Tomer, Bowden, Michaela, Whitton, Holly J, Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W, Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M, Sicinska, Ewa, Kulke, Matthew H, Chung, Daniel C, Bernstein, Bradley E, and Shivdasani, Ramesh A

Published
2019

6. Publisher Correction: Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors (Nature Medicine, (2019), 25, 8, (1260-1265), 10.1038/s41591-019-0493-4)

Author

Pathologie Groep Brosens, Cancer, Pathologie Pathologen staf, Pathologie, MS Endocriene Oncologie, Heelkunde Opleiding, MS CGO, Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M A, Brosens, Lodewijk A A, Deshpande, Vikram, Epstein, Charles B, Conemans, Elfi B, Morsink, Folkert H M, Graham, Mindy K, Valk, Gerlof D, Vriens, Menno R, Castillo, Carlos Fernandez-Del, Ferrone, Cristina R, Adar, Tomer, Bowden, Michaela, Whitton, Holly J, Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W, Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M, Sicinska, Ewa, Kulke, Matthew H, Chung, Daniel C, Bernstein, Bradley E, Shivdasani, Ramesh A, Pathologie Groep Brosens, Cancer, Pathologie Pathologen staf, Pathologie, MS Endocriene Oncologie, Heelkunde Opleiding, MS CGO, Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M A, Brosens, Lodewijk A A, Deshpande, Vikram, Epstein, Charles B, Conemans, Elfi B, Morsink, Folkert H M, Graham, Mindy K, Valk, Gerlof D, Vriens, Menno R, Castillo, Carlos Fernandez-Del, Ferrone, Cristina R, Adar, Tomer, Bowden, Michaela, Whitton, Holly J, Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W, Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M, Sicinska, Ewa, Kulke, Matthew H, Chung, Daniel C, Bernstein, Bradley E, and Shivdasani, Ramesh A

Published
2019

7. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors

Author

Divisie Beeld & Oncologie, Pathologie Groep Brosens, Cancer, Pathologie ICT innovatie & ontwikkeling, Pathologie Pathologen staf, Pathologie, MS Endocriene Oncologie, CTC, Heelkunde Opleiding, MS CGO, Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M.A., Brosens, Lodewijk A.A., Deshpande, Vikram, Epstein, Charles B., Conemans, Elfi B., Morsink, Folkert H.M., Graham, Mindy K., Valk, Gerlof D., Vriens, Menno R., Castillo, Carlos Fernandez del, Ferrone, Cristina R., Adar, Tomer, Bowden, Michaela, Whitton, Holly J., Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W., Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M., Sicinska, Ewa, Kulke, Matthew H., Chung, Daniel C., Bernstein, Bradley E., Shivdasani, Ramesh A., Divisie Beeld & Oncologie, Pathologie Groep Brosens, Cancer, Pathologie ICT innovatie & ontwikkeling, Pathologie Pathologen staf, Pathologie, MS Endocriene Oncologie, CTC, Heelkunde Opleiding, MS CGO, Cejas, Paloma, Drier, Yotam, Dreijerink, Koen M.A., Brosens, Lodewijk A.A., Deshpande, Vikram, Epstein, Charles B., Conemans, Elfi B., Morsink, Folkert H.M., Graham, Mindy K., Valk, Gerlof D., Vriens, Menno R., Castillo, Carlos Fernandez del, Ferrone, Cristina R., Adar, Tomer, Bowden, Michaela, Whitton, Holly J., Da Silva, Annacarolina, Font-Tello, Alba, Long, Henry W., Gaskell, Elizabeth, Shoresh, Noam, Heaphy, Christopher M., Sicinska, Ewa, Kulke, Matthew H., Chung, Daniel C., Bernstein, Bradley E., and Shivdasani, Ramesh A.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results